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Available online 29 April 2019Background: Extracellular vesicles (EVs) are secretedmembranous particles intensively studied for their potential
cargo of diagnostic markers. Efficient and cost-effective isolation methods need to be established for the repro-
ducible and high-throughput study of EVs in the clinical practice.
Methods: We designed the nickel-based isolation (NBI) to rapidly isolate EVs and combined it with newly-
designed amplified luminescent proximity homogeneous assay or digital PCR to detect biomarkers of clinical
utility.
Findings: From plasma of 46 healthy donors, we systematically recovered small EV (~250 nm of mean diameter;
~3× 1010/ml) and large EV (~560 nmofmeandiameter; ~5 × 108/ml) lineages ranging from50 to 700 nm,which
displayed hematopoietic/endothelial cell markers that were also used in spike-in experiments using EVs from
tumor cell lines. In retrospective studies, we detected picomolar concentrations of prostate-specific membrane
antigen (PSMA) in fractions of EVs isolated from the plasma of prostate cancer patients, discriminating them
from control subjects. Directly from oil-encapsulated EVs for digital PCR, we identified somatic BRAF and KRAS
mutations circulating in the plasma ofmetastatic colorectal cancer (CRC) patients,matching 100%of concordance
with tissue diagnostics. Importantly, with higher sensitivity and specificity comparedwith immuno-isolated EVs,
we revealed additional somatic alterations in 7% of wild-type CRC cases that were subsequently validated by fur-
ther inspections in the matched tissue biopsies.
Interpretation:We propose NBI-combined approaches as simple, fast, and robust strategies to probe the tumor
heterogeneity and contribute to the development of EV-based liquid biopsy studies.
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Extracellular vesicles (EVs) are membranous particles, composed of
a lipid bilayer, that are massively secreted in biological fluids, where
they are involved in cell-to-cell communication [1–3]. According to dif-
ferent mechanisms of biogenesis [4], EVs are classified into exosomes
and microvesicles (or ectosomes), derivatives of the endosomal system
or produced by outward budding of the plasmamembrane, respectivelythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
The abundance and biological content of heterogeneous EVs in bi-
ological fluids qualify them as an attractive source of diagnostic
markers. However, reproducible and efficient isolation methods
need to be established for application in clinical practice. Rapid ap-
proaches that minimize protein contaminants exploited the sur-
face charge of EVs to capture them.
Added value of this study
We designed a rapid and cost-effective procedure to obtain EVs in
a physiological pH solution, while preserving vesicles' integrity/
stability and minimizing particle aggregation. We exploited these
advantages to combine this approach with highly sensitive
immobilization-independent assays to detect cancer biomarkers,
i.e. specific proteins or RNA species present in EVs. We show
that a comprehensive isolation of EVs offers a strategic advantage
for detecting tumor biomarkers from liquid biopsy.
Implications of all the available evidence
This study indicates the possibility of detecting, from circulating
EVs, rare somatic alterations in driver genes thatmirror the hetero-
geneity of tumor cells present in the matched tissue biopsies.
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exosomes are generally smaller than 150 nm and microvesicles can
overlap to some extent, ranging from 100 to 1000 nm; insights into
their sub-cellular origin are usually obtained post-isolation by detecting
the enrichment of specific markers [6]. For these reasons, the term
small/large EVs can be also used to refer to a mixed population of vesi-
cles with a defined range of size [7]. Recently, EVs have been studied in
the frame of the modulation of the tumor microenvironment and in-
flammation [8]/immune surveillance [9], or also investigated as carriers
of therapeutics [10]. The high abundance of circulating EVs and a biolog-
ical composition reflecting the cell of origin [11] qualify them as attrac-
tive diagnostic tool [12]. This potential has been recently demonstrated
from liquid biopsies by detecting cancer biomarkers with recognized
clinical utility, for example in the case of circulating levels of EGFR in
lung cancer [13] and breast cancer [14] patients or EGFR mutations in
pulmonary adenocarcinoma patients [14,15]; in the case of KRASG12D
and TP53R273H mutations in patients with advanced or early-stage pan-
creatic cancer [16,17]; in the case of copy number variations that
matched genes frequently altered inmetastatic prostate cancer patients
[18].
However, the application of EVs into the clinical practice is still lim-
ited by low-throughput, time-consuming isolation procedures and the
sensitivity and specificity of the results are highly dependent on the
methods used to enrich them. Given their nanoscale dimensions,
many technical challenges have been addressed to isolate them with
purity and reproducibility [19]. Themethodsmore frequently employed
include differential and/or density gradient ultracentrifugation,
immunocapture, microfiltration/size exclusion, or precipitation with
hydrophobic agents [20]. The differential ultracentrifugation (UC) is
the most widely applied [21], as it concentrates the vesicles and allows
for size-based sedimentation of EVs according to the g-force applied
without interferences from chemical additives, especially in view of
downstreamapplications. In this case, the yield and the purity of the ob-
tained EVs [22] are influenced by different protocol settings and chal-
lenged by co-sedimentation of protein aggregates [19]. For these
reasons, new antibody-based strategies or EV-targeting probes havebeen developed to recognize and immobilize the vesicles for subse-
quently detecting specific biomarkers [23–25]. These methods offer ex-
cellent throughput for identifying co-expression of antigens that
decorate EVs, which should be deeply investigated in terms of quantita-
tive/spatial distribution as potentially influenced by the cell status [5].
Alternative rapid EV-isolation procedures proven to reduce protein
contaminants, in comparison with ultracentrifugation, exploited the
negative surface charge of EVs [26–28]. These approaches are based
on the principle that, under physiological conditions (pH N 5), heteroge-
neous EVs display negative fluctuations of zeta potential (ZP),which is a
physicochemical parameter that quantifies the surface charge of biolog-
ical particles [29]. ZP is highly dependent on pH, salt concentrations,
temperature, and on the specific biochemical composition of the parti-
cles themselves [30]. Technologies like dynamic light scattering (DLS)
[31] and tunable resistive pulse sensing (TRPS) [32] have been used to
monitor the ZP of heterogeneous EVs, that encompasses −40 to
−7 mV in PBS at pH 7.4 [33]. These values ensure the presence of a
net negative surface charge that has been exploited to capture EVs
and subsequently release them by modulating the pH and the ionic
strength in the elution buffer.
In thisworkwe describe an alternative strategy, named nickel-based
isolation (NBI), that exploits a matrix of beads properly functionalized
with nickel cations to capture heterogeneous EVs and the possibility
to efficiently reverse the binding using a synergy of chelating agents
(EDTA and citric acid) in PBS buffer (pH7.4). NBI allowed a rapid enrich-
ment of dimensionally heterogeneous (polydisperse) EVs in solution
preserving their integrity and stability.
We characterized the performances of NBI in comparison with the
gold standard differential ultracentrifugation and assessed the presence
of specific hematopoietic-endothelial antigens on the surface of plasma-
isolated EVs to ensure the unbiased enrichment of heterogeneous EV
lineages by NBI. Importantly, the possibility to directly use NBI-
isolated EVs as individual particles in no-wash, immobilization-
independent assays allowed us to implement the amplified luminescent
proximity homogeneous assay (alpha) and a new droplet digital PCR
(ddPCR) protocol to detect cancer-specific markers on EVs from the
plasma of oncological patients with an unprecedented resolution from
liquid biopsy.2. Materials and methods
2.1. Cell cultures
Glioblastoma cells U87-MG (ATCC® HTB-14™); breast adenocarci-
noma cell lines MCF7 (ICLC; HTL95021) and MDA-MB-231 (ICLC;
HTL99004), neuroblastoma SH-SY5Y (ATCC®CRL-2266™), prostate ad-
enocarcinoma PC-3 (ATCC® CRL-1435™), and melanoma SK-MEL-28
(ATCC® HTB-72™) cells were grown in DMEM, except for PC-3 cell
line that was cultured in standard conditions in RPMI 1640 Medium,
supplemented with 10% Fetal Bovine Serum, 2 mM L-glutamine, and
100 U/ml penicillin +100 μg/ml streptomycin (all from Life Technolo-
gies, Carlsbad, CA, USA) to obtain complete medium. Generally, to ob-
tain extracellular vesicles (EVs)-containing media, cells were initially
grown in complete medium until reaching 75% confluence (usually
48 h); then, after two gentle washes with PBS, cells were incubated
with serum-free medium for 24 h. Cells were plated in different plastic
formats according to the experiments to be performed, but the density
of them was kept constant at 3.2 ± 0.2 ×104/cm2 otherwise differently
stated in the figure legends.
Before starting NBI procedure, collected media were centrifuged at
2800g for 10 min and carefully transferred to new tubes.
For the experiments in Fig. 2a, dFBS condition refers to NBI per-
formed in media containing 100 K ultracentrifuged FBS at final concen-
tration of 10%. These media have been diluted 1:10 with PBS to reduce
viscosity of the solution.
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SY5Y,MCF7 and PC-3 cell lineswere plated in triplicates in 6-well plates
with these numbers per well: 3.4 × 105; 1.7 × 105; 8.5 × 104; 4.2 × 104;
2.1 × 104 and 1.0 × 104. After 48 h of incubation in complete medium,
cells were washed twice with PBS and then incubated for 24 h with
serum-free medium before starting with NBI protocol. In this case,
after removing EVs-containing media, adherent cells were fixed with
4% paraformaldehyde, stained with Hoechst33342 and washed with
PBS for high content imaging analysis using Operetta instrument
(Perkin Elmer). Images were acquired at 10× magnification and 50
fields/well were analysed by Harmony software. EVs were analysed by
TRPS using qNano (IZON Science).
2.2. EVs isolation by differential ultracentrifugation
EVs produced by U87-MG cells grown in T150 flasks (CLS430823-
50EA) were isolated by differential ultracentrifugation according to
the protocol by Di Vizio et al. [34] with minor modifications. Briefly,
after 24 h of incubation with cells serum-free media were collected in
falcon tubes and centrifuged at 2800g for 10 min at 4 °C to mainly re-
move cell debris and apoptotic bodies. Then, the supernatants were
transferred to ultracentrifuge tubes (Polyallomer Quick-Seal centrifuge
tubes 25 × 89 mm, Beckman Coulter) and centrifuged at 10,000g for
30 min at 4 °C in the Optima XE-90 (Beckman Coulter) instrument
with SW 32 Ti rotor. This step allowed to preferentially precipitate
larger particles (less apoptotic bodies, microvesicles), that were gently
resuspended in filtered PBS (Res1). Thereafter, supernatants were fur-
ther centrifuged at 100,000g for 70min at 4 °C to pellet smaller particles.
Pellets were resuspendend in filtered PBS (Res2). The volumes of Res1
and Res2 were pooled and stored a−80 °C or kept at 4 °C to proceed
with TRPS analyses. For experiments involving OptiPrep density gradi-
ent (ODG) preparations, we followed the protocol reported by Van
Deun et al. [35], but starting from a volume of 200 ul of PBS, that resus-
pended the pellet of 100,000 g ultracentrifuged particles, loaded on the
top of 5–40% iodixanol gradient. After ultracentrifugation, we pooled
the fractions 8 to 10 and analysed by immunoblotting the pellet ob-
tained by re-centrifugation at 100,000g for 2 h from a 3 ml solution.
2.3. Flow cytometry analysis of microvesicles
Vesicles obtained by differential ultracentrifugation or NBI were di-
luted in 0.22 μm filtered PBS and background signal was set up on fil-
tered PBS and the light scattering threshold level was adjusted to
allow an event rate of ≤5 events per second.
Light scattering detection was performed in log mode, the assigned
voltages for FSC and SSC were 300 and 310 V, respectively, and the
threshold was set at 200 for both signals. Acquisition was performed
at low flow rate and sampleswere properly diluted to avoid coincidence
and swarm effects. Bead standards of 1 and 10 μm (Invitrogen) were
used to set gates for microvesicles. A number of 10,000 events was
counted or at least 1 min recording for each sample. Sample acquisition
was performed on a FACS Canto flow-cytometer (BD Biosciences) and
data analysis using BD Diva software (BD Biosciences).
2.4. Nickel-based isolation (NBI)
Positively charged agarose beads (GE Healthcare, 17-5268-01) were
prepared with a suspension of 20 mg/ml in PBS containing 190 mM of
NiSO4 (Sigma, 656895). Residual amount of cationswas removed by re-
peated PBS washing and centrifugation and beads were stored at 4 °C
for up to 1 month.
The capture of EVs has been optimized using 20 μl/ml of beads from
the prepared suspension and entirely performed at room temperature.
An excess of beads ensured better reproducibility and maximal EVs re-
covery. Briefly, beads were gently added on the upper surface of the
EVs-containing medium and the solution placed in orbital shaking for30 min, well homogenized during incubation. Thereafter, tubes were
gently centrifuged (~200g) and then maintained in vertical position
for 5 min to allow beads to settle down by gravity. The elution buffer,
freshly prepared by diluting solution A (3.2 mM EDTA, ThermoFisher,
UltraPure pH 8.0, 15575020) and B (10 mM NaCl, Sigma, 450006, 45
μM citric acid, Sigma, 251275) in 0.22 μm-filtered PBS allowed compet-
itive EVs-beads dissociation and release of EVs in solution at physiolog-
ical pH (7.4).
2.5. Transmission electron microscopy (TEM)
The vesicles were visualized using conventional transmission EM
(TEM). Briefly, a 5 μl aliquot of a purified sample, fixed in elution buffer
with 2.5% formaldehyde,was applied to 300-squaremesh copper-nickel
grids coated with a thin carbon film. The grids were subsequently neg-
atively stained with 1% buffered uranyl acetate, pH 4.5, and observed
using a TEM FEI Tecnai G2 Spirit microscope operating at 100 kV and
equipped with an Olympus Morada side-mount 2Kx4K charge-
coupled device camera (magnification used: 20500× and 87,000×).
2.6. TRPS (tunable resistive pulse sensing)
Size and concentration of the EVs were characterized by TRPS using
qNano (IZON Science). An average of 500 particles were counted for
each sample, except for experiments performed in 6-well plates
(Fig. 2B, Fig. 3, and Fig. S4) or in samples where the particle rate was
below 100 particle/min, in which at least 2 min recording time was
used. NP200 (A40948, A43545, A43667, A43667), NP400 (A43592,
A44117, A44116), NP800 (A40542, A36164, A40548, A44118) and
N1000 (A40572) nanopores, stretched between 45.5 and 47 mmwere
used. Voltage was set in between 0.12 and 0.68 to achieve andmaintain
a stable current in the range of 95–130 nA, noise below 7–12 pA and
particle count rate linear. The calibration beads CPC100B (Batch ID:
B8748N), CPC200B (Batch ID: B6481M), CPC500E (Batch ID:
659543B), CPC800E (Batch ID: 634561B) and CPC1000F (Batch ID:
669582B) with mean diameters of 114 nm, 210 nm, 500 nm, 710 nm
and 940 nm, respectively, were from iZON Science. All the qNANO
data were recorded and analysed by Izon Control Suite v.3.
2.7. Protein competitive assay
The step of EVs elution has been challengedby a competitive assay in
which 10 ml of medium containing EVs deriving from U87 cells was
supplemented with 30 μg/ml of DH5α E. coli crude extract and with
15 μg/ml of purified histidine-tagged recombinant proteins (T7 RNA
pol, 110 kDa; HuR, 36 kDa; YTH, 23 kDa). Briefly, DH5α cells were
grown in LB medium until they reached an OD600 of 0.5 and were har-
vested by centrifugation at 6000g for 5 min. Pellet was resuspended in
3 ml of DMEM medium +1 μg/ml lysozyme and sonicated at 4 °C in
water bath for 7 cycles (40 amplitude, 7 s on, 10 s off). Lysate was clar-
ified by centrifugation at 13,000g for 20 min and then filtered with 0.2
μm membrane disposals prior to be spiked to the EVs-containing me-
dium. Histidine-tagged recombinant T7 RNA polymerase was kindly
provided by Dr. S. Mansy's lab (CIBIO, University of Trento); recombi-
nant HuR [36] and YTH [37] proteins produced and purified as previ-
ously described.
NBI was performed with incubation times and reagents already de-
scribed, except for the gradient of elution solutions as indicated in
Fig. 1b. Protein samples were quantified using BCA and Bradford assays
according to the manufacturer's instructions. Equal volume of eluates
were loaded on 12% SDS-PAGE for subsequent Sypro Ruby staining or
western blotting using a 1:1000 dilution of a primary anti-histidine an-
tibody (ab1187).
Number and size of recovered particles were analysed by TRPS, in all
the fractions, using NP800, NP400, and NP200 nanopores.
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of EVs isolated from the media of three T150 flasks per each condition:
UC and NBI) were separated by a pre-cast gradient SDS-PAGE (Bolt™
4–12% Bis-Tris Plus Gels, 12-well, Invitrogen) and transferred to a
polyvinylidene difluoride membrane (Amersham Hybond P 0.2 μm
PVDF) overnight. After blocking with 5% nonfat milk in TBS-T (10 mM
Tris, pH 8.0, 150 mM NaCl, 0.1% Tween 20) for 60 min, the membrane
was incubated in 1% milk TBS-T with antibodies against Apo B100
(ab7616, Abcam, 1:1000), Apo A1 (ab7613, Abcam, 1:1000), Syntenin
(1:1000), Flotillin-1 (1:1000), Alix (1:1000) at 4 °C overnight. Mem-
branes were washed three times for 5 min and incubated with horse-
radish peroxidase-conjugated anti-goat, anti-rabbit or anti-mouseFig. 1. Rapid purification of EVs by NBI preserving their integrity, dispersity, and stability in so
susceptible to electrostatic interactions. Using 1–3 mM of chelating agents, TRPS analyses det
stationary phase in contrast to nucleic acids (A260), proteins (A280), or pre-stained ssRNA (
rapid NBI procedure are depicted. b) Competitive assay in serum-free medium containing 5
(T7p07, HuR, YTH domain). Two parallel gels were exposed to SYPRO Ruby or blotted on PVD
The 1× solution is the optimized buffer and the flow-through (FT) is the medium after beads
to two independent experiments. c) Transmission electron microscopy (TEM) acquisitions, wi
magnification, of NBI samples fixed with 2.5% paraformaldehyde in the elution buffer. The or
side for better visualization. d) Western blot analyses on EV lysate (recovered by 14 × 106 cel
diameter of 181 ± 23.8 nm recovered by ultracentrifugation (UC) or NBI. The same experime
Rho) of liposomes prior UC or NBI processing. f) EVs were isolated by UC or NBI from 3 ml of s
Repeated measurements by TRPS have been performed until 52 days post-purification and th
software v.5.secondary antibodies for 1–2 h. Blots were washed with TBS-T three
times and the immunoblot signal was revealed using the chemilumi-
nescent ECL Select detection reagent (GE Healthcare Amersham, UK).
2.8. Preparation of exosome-like liposomes
The lipid composition of exosome-like vesicles was: 20% mol egg
phosphatidylcholine, 10% mol egg phosphatidylethanolamine, 15%
mol dioleoylphosphatidylserine, 15% mol egg sphingomyelin, 40% mol
cholesterol (adapted from literature [38,39]). Lipid films were formed
by removing the organic solvent (i.e. chloroform) from a lipid solution
by rotary evaporation and vacuum drying for at least 1 h. Lipids at alution. a) At pH values N5 the net negative charge of membranous particles makes them
ected particles in the 500–700 nm range of size, selectively eluted from a functionalized
RNA Y) pre-incubated with nickel-agarose beads. The procedural steps highlighting the
00 μg/ml of DH5α protein extract and of 50 μg/ml each of purified his-tagged proteins
F membrane to detect hstidine (tag known to confer the strongest interaction with Ni).
sedimentation. qNANO analyses with indicated nanopores were performed and SD refers
th 3 fields at 20.500× (1 μm) + 5×magnification and 3 fields at 87.000× (200 nm) + 5×
iginal scale bars are embedded at the bottom right, but also added manually on the left
ls) and on 1% total cell lysate (TCL) of U87 cells. e) Mixture of 4.2 × 109 liposomes with a
nt has been replicated with phosphatidylethanolamine-rhodamine (5 ng/ml) stain (PE-
erum-free medium of U87 cells and analysed at (t0) or after 24 days (t24, stored at 4 °C).
e relative half-live of the 600 nm populations have been calculated with GraphPad Prism
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orously to give multilamellar liposomes, whichwere further exposed to
6 cycles of freezing and thawing. Exosome-like liposomes were pre-
pared by extruding a suspension of multilamellar liposomes with a
two-syringes extruder (LiposoFast Basic Unit, Avestin Inc.). Thirty-one
passages were performed through two stacked polycarbonate filters
(Millipore) with pores of different average diameters to obtain differ-
ently sized vesicles [40], thenmeasured by photon correlation spectros-
copy with a Zeta Sizer instrument (Nano-ZS, Malvern Instruments).
2.9. Blood samples
Plasma samples derived from patients with metastatic colon cancer
were provided by the IRST Cancer Center. All patients gave informed
consent before blood sampling, approved by the Local Ethics Commit-
tee. Patients' tumors were characterized for BRAF status by MassARRAY
(Sequenom, San Diego, CA, USA) using the Myriapod Colon status
(Diatech Pharmacogenetics, Jesi, Italy). Plasma was obtained from pe-
ripheral blood collected in EDTA-tubes, after centrifugation at
3000 rpm for 15 min, and stored at−80 °C until EV isolation.
Whole blood from healthy donors were collected at Meyer
Children's University Hospital. Plasma sampleswere collected into com-
mercially available anticoagulant-treated tubes EDTA-treated (lavender
tops), serum samples in red topped tubes. The venous blood in EDTA
tube was shipped on cold packs from hospital blood collection unit to
the laboratory. Informed consent were obtained from donors before
the sample analysis.
Plasma has been obtained by removing cells after centrifugation for
10 min at 2000g using a refrigerated (4 °C) centrifuge (Eppendorf 5702
R, Milan, Italy). Serum samples have been obtained allowing the blood
to clot by leaving it undisturbed at room temperature for 30 min. The
clot has been removed by spin down at 2000g using a refrigerated (4
°C) centrifuge (Eppendorf 5702 R, Milan, Italy). Blood count were per-
formed using a Sysmex XE-5000 hematology analyzer (Sysmex
America, Mundelein, IL). The analytic procedure was conducted accord-
ing to the manufacturer's instructions.
Blood from metastatic prostate cancer patients was obtained at
Weill Cornell Medicine (WCM) after informed consent (IRB
#1305013903). Whole blood (Streck Cell-Free DNA BCT) was centri-
fuged at 1600 g × 10 min at 4 °C within 3 h after blood collection. The
plasma layer was transferred to 2 ml microcentrifuge tubes and centri-
fuged at 16,000 g × 10 min at 4 °C. The plasma was then collected and
stored at−80 °C. Complete blood counts (CBC) was performed in the
WCM clinical lab and results obtained from chart review.
Immunodepletion of NBI-purified vesicles has been performed using
biotinylated anti CD235a (130-100-271) and anti CD41a (130-105-608)
from Miltenyl Biotec, anti-AL-CAM (sc-74558), anti-MEL-CAM (sc-
18837), anti CD45 (sc-1187) from SantaCruz Biotechnology, and
streptavidin (11205D) or protein-G (10003D) dynabeads from Thermo
Fisher Scientific. Vesicles after beads precipitation have been measured
by qNANO and normalized to the number of particles in the counterpart
control samples with equivalent amount of biotin (Sigma, B4501).
2.10. Tumor sample analysis
Formalin fixed and paraffin included (FFPE) patients' tumor sam-
ples, used for routinary molecular diagnostic, were selected for contain-
ing an area of at least 50% of tumor cells, based on hematoxylin and
eosin staining. Tumor genomic DNA was extracted with QIAamp DNA
Micro kit (QIAGEN, Hilden, Germany), following the manufacturer's
protocol, and DNA quantity and quality was determined at Nanodrop
(CELBIO, Milan, Italy). Characterization of BRAF status was performed
by Pyrosequencing with the anti-EGFR MoAb response® BRAF status
assay (Diatech Pharmacogenetics, Jesi, Italy): 50 ng of starting FFPE ge-
nomic DNA were amplified and reactions were run on the PyroMark
Q96 ID system (QIAGEN), according to Diatech Pharmacogeneticsprotocol. For samples 7, 12, 13, 23, and 26, Qualitative detection of
BRAF-V600E and KRAS-G12D/G12C mutations was repeated on 30 ng
of tumor DNA, by using either the Easy®BRAF kit or the Easy®KRAS
kit, on Corbett Rotor-Gene 6000 (QIAGEN), followingmanufacturer's in-
structions (Diatech Pharmacogenetics). The assay allows the detection
of low percentages of mutated allele by real-time amplification with
sequence-specific probes: positivity for BRAF-V600E was considered
over the internal BRAF control, as a delta Ct lover than 12.5 cycles, and
setting the detection threshold on 0.04, according to the guidelines of
Diatech Pharmacogenetics.
2.11. RNA extraction
Total RNA was extracted using QIAzol reagent (QIAGEN) according
to the manufacturer's instructions with several modifications. Briefly,
100 μl of QIAzol was added directly to the beads before the elution
step of NBI, vortexed and incubated for 5min at room temperature, sup-
plemented with 20 μl of chloroform, shaken vigorously for 15 s and in-
cubated at room temperature for 3 min. Phases were separated by
centrifugation at 12,000g for 15min at 4 °C, and the upper phasewas re-
covered. After addition of 1 μl of glycogen (20 mg/ml) and 100 μl of
isopropanol, RNA was precipitated overnight at−80 °C. After centrifu-
gation at 12,000g for 10 min, RNA pellets were washed with 75% etha-
nol, centrifuged as above and resuspended in 10 μl RNase-free water.
RNA was quantified using the Bioanalyzer RNA 6000 Pico Kit (Agilent
Technologies) following the manufacturer's instructions.
2.12. Amplified luminescent proximity homogeneous assay (alpha)
Reactionswere carried out in 384-Optiplate (Perkin Elmer) in a final
volume of 20 μl. Assay was optimized in PBS using 15 μg/ml of nichel-
chelate AlphaLisa Acceptor beads and 10 μg/ml of streptavidin-Donor
beads with serial dilutions of antibody to identify hook point. The pres-
ence of surface markers was analysed in dose-response with serial dilu-
tion of EVs, previously characterized by TRPS. EVs were purified by NBI
from plasma of healthy donors or from serum-free medium of tumor
cell lines. Alpha counts were revealed by Enspire instrument (Perkin
Elmer) after 90min of plate incubation in the dark at room temperature.
We used a biotinylated antibody against human PSMA (Cusabio, CSB-
PA018865LD01HU) and a recombinant his-tagged PSMA (Origene,
NM_002786) for a standard curve quantification.
2.13. Reverse transcription and droplet digital PCR
Reverse transcription was performed usingmiRCURY LNA Universal
RT microRNA PCR, Universal cDNA Synthesis Kit II (Exiqon) following
the manufacturer's instructions with the following reaction composi-
tion: 2.3 μl of 5× reaction buffer, 1.15 μl enzyme mix, 0.5 μl synthetic
RNA spike-in and 7.5 μl of template total RNA.
QX200TM Droplet DigitalTM PCR System (BioRad) was used to
quantify mRNA copies using EvaGreen chemistry and the following
primers: 5′-CAACGAATTTGGCTACAGCA-3′ and 5′-AGGGGTCTACATGG
CAACTG-3′ for GAPDH; 5′-GATTTTGGTCTAGCTACAGA and 5′-GGATTT
TTATCTTGCATTC for BRAF.
The direct encapsulation of EVs into oil droplets has been performed
using isolated EVs as input sample, EvaGreenmastermix supplemented
with 5 U/ml of WarmStart® RTx Reverse Transcriptase (NEB) and with
3 mMmagnesium sulphate. The standard protocol of ddPCR included a
starting 10 min step at 55 °C followed by 5 min at 65 °C.
We optimized the procedure working with 102–106 polydisperse
EVs to obtain at least 15,000 droplets in each assay.
2.14. Statistical analyses
The data and the number of independent experiments are indicated
in the relative figure legends. Anova, t-test, and Pearson r coefficient
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considered statistically significant when P value was b0.05 (*), b0.01
(**), b0.001 (***).
3. Results
3.1. Capture and competitive elution of extracellular vesicles by nickel-
based isolation
The versatility of NBI is based on the scalable range of positive charge
conferred by nickel cations and on the surface area of a stationary phase.
We used a suspension of agarose beads functionalized by increasing
concentrations of nickel sulphate (50–300 mM). To have an indication
on the number of particles recovered from the beads, we analysed the
particles obtained from 10 ml of serum-free media incubated with
U87 glioma cells in parallel with differential ultracentrifugation (UC).
As estimated by flow-cytometry and only for events ≥0.5 μm, we
reached a conditionwhere the observed number of particles was equiv-
alent for the two approaches and, in case of NBI, dependent on nickel
cations, since no particles were recovered by non-functionalized beads
(Fig. S1). These results have been obtained by functionalizing a suspen-
sion 20 ml/ml of beads, 24 ± 7 μm in size, with 200 mM of nickel
sulphate.
Since different molecules can efficiently interact with a nickel ma-
trix, we next used TRPS (qNANO instrument) [41] and spectroscopic
analyses to analyse the number of particles eluted from the beads in
the presence of a phosphate buffered saline (PBS) solution containing
chelating agents (elution buffers), i.e. EDTA and citric acid (CA), trying
to design an elution buffer tailored for EVs.Weused 10ml ofmedia con-
taining U87-derived secretome and, in control experiments, we used
nickel-beads pre-incubated with U87-purified input DNA, input pro-
teins, or input RNA, to understand the specificity of the elution buffer
in the reversible binding of the different biomolecules. We monitored,
by absorbance and fluorescence scan, both elution buffers and beads
(in this case by further normalizing the signal to the 350 nm peak of
nickel beads). Since the absorbance of DNA and RNA molecules has
the same peak at 260 nm, we pre-stained the beads with pyronin Y in
order tomeasure a specific fluorescence signal for the RNA.We detected
a significant number of particles (2–5 × 109/ml, 50–700 nm using 3
nanopores) with the elution buffer containing a low millimolar range
of chelating agents (molar ratio EDTA:CA of ~1:70; elution buffer 1×),
which resulted to an early dissociation of qNANO detected particles
(Kd of 1.15 ± 0.37 mM−1 for EDTA in the presence of 45 μM of CA) at
pH 7.4. Notably, no absorbance or relevant fluorescence signals were
obtained using the elution buffer 1×, in contrast of elution buffers con-
taining N3 mMof EDTA. Representative data and the steps of the proce-
dure are schematically shown in Fig. 1a.
To validate these observations with complementary approaches, we
challenged this selectivity by competitive assays in a protein-enriched
system. We supplemented 10 ml of DMEM, containing the secretome
of U87 cells, with crude extracts of DH5α E. coli cells (from pelleted bac-
teria) andwith 3 purified histidine-tagged proteins of different molecu-
lar weight (MW, Fig. S2), since nickel matrices are conventionally
exploited to purify 6xHis recombinant proteins. We performed NBI in
the mixture and eluted the particles with a gradient of chelating agents
in PBS, keeping the reference of the elution buffer 1× solution. Captured
proteins started to bedetected/elutedwith a 1.5× solution, as evidenced
by SDS-PAGE, SYPRO Ruby staining and immunoblotting using an anti-
his antibody, that firstly detected the recombinant proteins with higher
MW (Fig. 1b). In the same samples, TRPS analyses with 3 nanopores de-
tected 50–700 nm particles with 0.5× and 1× elution buffers,
confirming the competitive dissociation of EVs from the beads in the
low millimolar range of chelating agents. According to Bradford or
BCA assays, we quantified 20–25 μg/ml (0.5× + 1× condition, Fig. 1b)
of proteins that mirrored a total of 2 × 109 particles detected by the
nanopores.The strategy of using EDTA combined with citric acid provided a
valuable alternative to preserve the pH and the biological sample from
high concentrations of salts [27] that can affect vesicles' integrity, as
shown in Fig. S3.
We evaluated the extent of particles obtained with elution buffer 1×
by transmission electronmicroscopy (TEM; 20,500× and 87,000×mag-
nifications, Fig. 1c). Wide-field acquisitions of NBI samples showed a
broad dispersity of vesicles with an enrichment at 80–120 nm in size.
Although we optimized these experiments with reduced concentration
of formaldehyde and dry time to minimize the shrinkage effects [5], we
used DLS to calculate the polydispersity (index of 0.61 ± 0.05), which
mirrored the data obtained by TRPS. Western blot analyses on those
samples showed that NBI-isolated EVs were positive to endosome-
associated proteins, such as Alix and CD63 markers [42], or also found
to the plasma cell membrane, such as Flotillin-1 [43], and negative to
Golgi markers (GM130, Fig. 1d) [20], at least indicating the presence
of exosome and microvesicle markers in the mixed populations of the
vesicles we isolate.
With the aim to investigate the impact of mechanical forces exerted
during the NBI procedure, we produced liposomes with an “exosome-
like” lipidic composition [39] and spiked them in 10 ml of DMEM
(Fig. 1e). Similar to the EVs in the same conditions, the average zeta po-
tential of these preparationswas−15.2mV, as determined byDLS. Test-
ing a small volume (0.5 ml) of media, both NBI and UC allowed near full
recovery (98.6%) of input liposomes with a mean size of ~190 nm, al-
though with a slight shift of ~10 nm of diameter in UC samples (orange
vs red curve). Additional experiments performed with liposomes that
we pre-stained with the lipophilic phosphatidylethanolamine-
rhodamine (PE-Rho) dye evidenced a coalescent effect (N40 nm shift)
of PE-Rho UC vesicles, not observed with PE-Rho NBI vesicles. These
data demonstrate that the elution buffer used for NBI minimizes parti-
cles aggregation. We next interrogated the turnover of vesicles stored
at 4 °C after purification by NBI or UC (Fig. 1f, left). We focused on par-
ticles ≥300 nm, more vulnerable than smaller vesicles to different stor-
age conditions [44]. In UC samples, at 24 days post-isolation (t24), the
600 nm population originally present was virtually replaced by a popu-
lation of ~300 nm. Strikingly, NBI samples retained the 86% of the orig-
inal EV population, still detectable using the same nanopore (Fig. 1f,
middle). A kinetic analysis evaluating the size-shift of the 600 nm test
population revealed a half-life of N50 days for NBI EVs, in contrast to
7.35 days for UC EVs (Fig. 1f, right). Collectively, these data indicate
that polydisperse EVs can be selectively enriched by NBI preserving
their integrity and stability in a near physiological pH solution.
3.2. Scalable and reproducible isolation of polydisperse EVs from cancer cell
lines and the plasma of healthy volunteers
To assess the robustness of NBI in cell-based systems, we purified
EVs secreted by U87 cells seeded at different densities, in 6-well plates,
as indicated in Fig. 2a.We processed 1ml ofmedia and analysed the dis-
tribution of purified particles by TRPS using NP400, NP200, and NP100
nanopores. Isolated EVs displayed a continuous distribution, from ap-
proximately 50 to 700 nm in diameter (as compared with 3 different
sets of iZON recommended calibration beads), characterized by at
least two peaks of enriched vesicle populations showing ~200 and
~600nmofmean diameter, respectively.We referred these two EV pop-
ulations to as small EVs (sEVs) and large EVs (lEVs), respectively, while
being aware of the unknown sub-cellular origin of individual NBI-
isolated EVs [5]. The global number of isolated vesicleswas proportional
to the number of seeded cells, with a global coefficient of variation (CV)
of 6.14% (n=9 forNBI 1, 2, and3) for both sEVs (197±26nm) and lEVs
(595 ± 37 nm), underlying the high reproducibility of NBI. We did not
observe a statistically significant variation (P = .459) comparing EVs
from EV-depleted serum (dFBS) [45] and serum-free media (NBI 1), in-
dicating that a reliable EV isolation can be started from relatively viscous
solutions upon dilution with PBS. Interestingly, the efficient isolation of
Fig. 2.NBI efficiently isolates EVswith high reproducibility fromdifferent biological fluids. a) The reproducibility of NBI has been tested in serum-freemedia of U87 cells seeded at different
density, in 6-well plates, as indicated (NBI 1, 2, and3). Ten% ultracentrifuged FBS (dFBS) condition showed substantial overlapwithNBI-1 results. Plots are representative of 3 independent
experiments and global CVwas 6.1%. b) Distribution of NBI-isolated EVs have been analysed for different cell lines, as indicated. SH-SY5Y cells showed substantial reduction in releasing
both vesicle populations (**P value= .006, F= 70.13, and *** b 0.0001, F= 30.84, using one-way ANOVA and Bonferroni's post-test). SD refers to 3 independent experiments. c) NBI was
applied to 0.5 ml of plasma obtained from healthy volunteers. The relative distribution of EVs (representative original profiles are shown in Fig. S5b) has been evaluated by TRPS analyses
using 3 nanopores with the obtained concentrations, per milliliter of plama, of the small and large EV populations.
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using as low as 103 cells/cm2 (Fig. S3). We observed a linear release of
sEVs as a function of cell density, and an faster release of lEVs, as already
suggested for microvesicles [5], possibly related with different bioge-
netic mechanism, intrinsic stability and/or cell-mediated turnover that
correlate with particle size or composition [46]
We next characterized the EVs recovered from MCF-7, PC3, MDA-
MB-231, and SH-SY5Y tumor cell lines (Fig. 2b).We observed an equiv-
alent distribution of isolated EVs in terms of size and concentration,
with the exception of the SH-SY5Y cells that demonstrated lower pro-
pensity to release both vesicle populations.
Since EVs are secreted in the blood by many cell types [47], we ap-
plied NBI to isolate EVs from the blood of healthy volunteers (Fig. S4).
We analysed the abundance of isolated EVs in plasma and in the
serum (n=9) and clearly observed a 6-fold enrichment of EVs purified
from plasma (Fig. S5a).We therefore performed NBI on (0.5ml) plasma
of 46 donors to assess the general distribution of EVs isolated from
healthy subjects. The mean age of the volunteers was 45 ± 10 years.
The profile of NBI-isolated EVs (Fig. S5b) was characterized by at leasttwo enriched populations showing a quantitative ratio of ~55:1: the
first one with a mean diameter of 249.5 ± 36.71 nm (sEVs) and a con-
centration of 30.56 ± 25.78 × 109 per milliliter of plasma; the second
one with a mean size of 564.4 ± 57.3 nm (lEVs) and a concentration
of 5.49 ± 3.09 × 108 per milliliter of plasma, as indicated in Fig. 2c.
3.3. Characterization of plasma EV lineages by combined immunocapture
In line with other reports [48,49], mixed populations of circulating
vesicles in healthy individuals are positive to hematopoietic or endothe-
lial cell markers. We therefore investigated whether specific hemato-
poietic surface markers can be instrumental for the characterization of
isolated EVs.Wemeasured the number of plasma-isolated EVs left in so-
lution after incubation with CD235a (marker of erythrocytes [50]) or
CD41a (marker of platelets [51]) antibodies, i.e. immunodepleted sam-
ples. We observed a reduction of about 20% of the original population of
microvesicles and of about 60% of sEVs using the CD235a. On the other
hand, this trendwas opposite using the CD41a,which showed preferen-
tial recognition of lEVs (Fig. 3a). These results indicate that plasma
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derlying the derivation from different cells/progenitors. In addition,
these results are in line with other reports indicating that platelet-
derived microvesicles (range of size N300 nm) are abundant in the
blood of healthy individuals [52,53].
With the aim to recognize specific EV lineages fromamixture of NBI-
isolated polydisperse vesicles,we performed combined immunocapture
experiments with a known amount of tumor-derived EVs spiked in the
human plasma. We added 109/ml EVs isolated from plasma to 109/ml
EVs isolated from the media of melanoma SK-MEL-28 cells. After NBI,
we incubated the mixture of isolated vesicles with CD235a, CD41a,
and CD45 antibodies (known to be expressed from leukocytes [54]
but not from SK-MEL-28 cells [55]). After the immunoprecipitation (or
immunodepletion) of CD235a, CD41a, and CD45 vesicles, the MEL-
CAM antibody (CD146, expressed on the surface of SK-MEL-28 cells)
still recognized the 64% of input EVs (light green vs light grey bars) pos-
itive to the epithelial marker, in contrast to the AL-CAM (CD166) anti-
body which resulted as an experimental negative control (Fig. 3b).
Therefore, specific hematopoietic markers could be instrumental to
fractionate plasma NBI-isolated EVs into distinct EV lineages.Fig. 3. NBI unbiasedly isolates different EV lineages from blood and allows to use EVs as indiv
antigens, biotinylated anti-CD41a and CD235a antibodies, were used to characterize plasm
volumes and incubated with biotinylated antibodies (CD41a or CD235a) + streptavidin dyna
in solution are shown. * P value b .05; ***P value b .001. b) 109/ml plasma EVs, together wit
human plasma. Indicated biotinylated antibodies were incubated for 60 min and, after strep
One-way ANOVA-Bonferroni have been used to calculate the statistical significance (*P value
antigens on individual, polydisperse EVs. Streptavidin-coated Donor beads recognize the an
interact with EVs and emit a fluorescent signal when in proximity of excited Donor beads. Sa
of two healthy donors (#1, #2) and from SK-MEL-28 melanoma cells. d) Cells lines expressi
performed on cell lysates. EVs were isolated by NBI or UC from the corresponding media of t
then evaluated, using anti-CD81 biotinylated antibody for plate-coating in the case of ELISA (c
Acceptor beads in the case of ExoScreen. The specific, background-subtracted signals were nor
isolated by UC. 10 K and 100 K indicate the g forces applied in the two protocols of UC, resp
plasma deriving from patients with advanced prostate cancer. Left: The relative number of EVs
One-way ANOVA-Bonferroni have been used to calculate the statistical significance. Right:
standard curve with purified recombinant histidine-PSMA, 1 in the Y axis corresponds to ~35 pImportantly, the results obtained by these experiments indicated that
intact, polydisperse EVs obtained by NBI form a homogeneous suspen-
sion of individual particles that could be exploited in no-wash,
immobilization-independent assays.
3.4. Ultrasensitive detection of surface antigens on plasma EV lineages from
healthy subjects and prostate cancer patients by NBI-alpha assay
Given their abundance in the blood, EVs can offer immediate advan-
tage in liquid biopsy analyses for biomarker detection [56]. By NBI we
can recover polydisperse EVs from biological samples and obtain a sus-
pension of individual particles in solution. We therefore verified the
possibility of applying NBI-extracted EVs to versatile homogeneous as-
says to perform ultrasensitive biomarker detection.
We adapted the amplified luminescent proximity homogeneous
assay (alpha) [57] technology to detect surface antigens on NBI-
isolated EVs. Following the notions obtained on the dispersity of NBI-
isolated EVs, we designed the alpha assay using nickel-charged Accep-
tor beads in combination with streptavidin-Donor beads recognizing
the antigen of interest through biotinylated antibodies (NBI-alpha,idual particles in homogeneous assays to detect surface antigens. a) Hematopoietic cells'
a isolated EVs. Isolated EVs (2 × 108/ml), for a total of 15 samples, were divided in 2
beads. Supernatants were analysed by qNano instrument and the distribution of EVs left
h 109/ml EVs isolated from media of SK-MEL-28 cells were spiked in 1 ml of post-NBI
tavidin-dynabeads precipitation, TRPS analyses were performed on EVs left in solution.
b .05; **P value b .001). c) Diagram describing the alpha assay designed to detect surface
tigen-specific biotinylated antibody; positively-charged nickel-chelate Acceptor beads
turation curves were obtained as function of number of EVs purified by NBI from plasma
ng high, intermediate, or low levels of CD146 protein are indicated by immunoblotting
he three cell lines. The relative performances of different detection methods have been
oupled with anti-CD146 and HRP-conjugated secondary antibodies) or conjugation with
malized to IgG signals of individual experiments. EVs for ELISA and ExoScreen have been
ectively. SD refers to two independent experiments. e) NBI was performed on 1 ml of
is plotted for healthy donors (50–55 years) and for prostate cancer patients (N60 years).
the relative levels of PSMA on 105 EVs were detected by NBI-alpha. According to the
g/ml of PSMA in solution. SD refers to 3 independent experiments.
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(#1 and #2) and of SK-MEL-28-isolated EVs as function of the signal ob-
tained with biotinylated CD235a, CD41a, and CD45 antibodies. In the
case of plasma EVs, the saturation curves obtained showed three to
four times enhanced binding of CD235a with respect to CD41a and
CD45, with a background signal for the epithelial marker CD146 eve
using 106 EVs (Fig. 3c, bottom left and right). Consistently with results
in Fig. 2c,d, the CD235a antibody was the most efficient in recognizing
a significant fraction of plasma-isolated EVs. In the case of EVs released
from SK-MEL-28 cells, the signal of the CD146 antibody showed a dose-
response curve, in contrast to the CD235a, CD45, and CD41a antibodies
(Fig. 3c, top right), confirming the exposure of the CD146 protein on the
EVs deriving from melanoma cells. All these experiments were per-
formed in 20 μl, using ~2% of the solution containing plasma EVs and
~20% of the solution containing EVs recovered from 3 × 105 SK-MEL-
28 cells.
To challenge this approach in terms of sensitivity and accuracy, we
used three cell lines expressing high (SK-MEL-28), intermediate
(HeLa), or low (Jurkat) levels of the CD146 protein (see immunoblot
in Fig. 3d). We isolated EVs using NBI or UC and evaluated 2 additional
techniques (ELISA [58], ExoScreen [57]) for CD146 detection on EVs.
Globally, all the results obtained were consistent with relative expres-
sion levels of endogenous CD146. The NBI-alpha demonstrated a higher
dynamic range and themost performant detection (N5 times) of CD146
on EVs isolated from the most challenging Jurkat cells (FC = 4.6,
Fig. 3d). By comparing the alpha assay results with samples enriched
in large EVs (sedimented at 10,000 g) or in small EVs (sedimented at
100,000 g), respectively obtained by UC) [59], we attributed the advan-
tage of NBI-alpha in detecting the antigens on less aggregated particles
(Fig. 1e).
We validated the NBI-alpha approach by detecting the prostate can-
cer specific membrane antigen (PSMA) on EVs isolated from plasma of
prostate cancer patients (Fig. 3e). First, we analysed the distribution of
EVs isolated from plasma of healthy subjects (age of 50–55 years) and
from plasma of ten patients (N60 years)withmetastatic prostate cancer
(Fig. 3e). In line with other reports [60,61], we found a statistically sig-
nificant increase (of about one order ofmagnitude) in the number of re-
covered EVs in the cancer patients (Fig. 3e, left). The Pearson r value of
the correlation with counts of RBCs/WBCs/PLTs was 0.88 (Table S2).
Using 105 EVs in the NBI-alpha assay, we detected higher levels of
PSMA (mean P value b .001) in patients' EVswith respect to the healthy
controls, reaching the sensitivity of picomolar concentration of PSMA
(Fig. 3e, right) as determined by standard curve with his-tagged
PSMA. Therefore, we specifically detected the enrichment of this surface
marker on a fraction of the EVs isolated from the plasma of prostate can-
cer patients.
3.5. Ultrasensitive detection of RNA enclosed in EV lineages from plasma of
healthy subjects and colon cancer patients by NBI-ddPCR assay
EVs can selectively or stochastically entrap nucleic acids [5]. The
growing interest in exploiting EVs for cancer diagnostics relies with
the potential identification of new biomarkers and of clues mirroring
the genetic heterogeneity of tumor cells. Therefore, the potential clinical
application requires a sensitive approach to distinguish EV sub-
populations and to infer, at least qualitatively, the diversity of tumor
cells that have originated them. We analysed the nucleic acid content
of polydisperse EVs (50–700 nm) isolated from the plasma of healthy
donors (n= 47) and we detected RNA, as demonstrated by automated
electrophoresis profile following RNAse treatment (Fig. S7a). One of the
most highly sensitive reported technology to detect fractions of mu-
tated transcripts enclosed within EVs is the droplet digital PCR
(ddPCR) [17,62].We therefore applied a standard ddPCR protocol to cal-
culate the absolute number of GAPDHmRNAs in all the samples starting
from ~3 × 109 EVs (Fig. 4a and Fig. S7b). The system was sensitive
enough to correlate the number of mRNA copies with the relativecounts of PLTs (Pearson r: 0.623; Fig. 4b), blood components already
recognized as major producer of GAPDH [63]. Interestingly, given the
quality of the EV samples obtained by NBI (in terms of non-coalescent
particles), we had a chance to implement the ddPCR assay by directly
encapsulating NBI-isolated EVs into the oil droplets, with a reaction
mix containing a thermostable reverse transcriptase to perform a one-
step amplification of the RNA fragment of interest (Fig. 4c). In these ex-
perimental conditions, specific nucleic acids can be rapidly detected
from a discrete number of individual EVs and without the step of RNA
extraction. Notably, particles isolated by UC failed to generate the ex-
pected number of oil droplets (N12,000), indicating that a direct encap-
sulation can be in this case hampered by aggregated vesicles.
We challenged the diagnostic performances of this NBI-ddPCR pro-
tocol by a retrospective analysis of a cohort of metastatic colon cancer
patients. Patients were previously enrolled in a randomized phase III
clinical trial for chemotherapy alone or in combination with
bevacizumab [64,65]. All of the patients were analysed for the KRAS
and BRAF status, two biomarkers that have a profound impact for pa-
tients in terms of clinical management and therapeutic options for
CRC patients. We isolated EVs by NBI from the plasma of 21 cases with
6 additional blood draws collected from one single patient during the
treatment (longitudinal liquid biopsy). The molecular characterization
was performed by pyrosequencing on formalin-fixed, paraffin-
embedded (FFPE) tissue DNA and indicated the presence of the BRAF
V600E mutation in 5 out of 21 patients (~24%, samples C02, C11, C14,
C20, and C25). The mutation was confirmed in the sample C03, a
5 months' later blood draw of the sample C20. In the samples we re-
ceived, no mutations in KRAS were reported, except for the variant
K117N in the sample C07. We analysed the samples in blind as in the
order reported in Table S3.
First, we report that the levels of EVs recovered fromplasma of colon
cancer patients were strikingly higher in comparison to those of healthy
donors (Fig. 4d). The correlation coefficient was 0.93 with relative
counts of RBCs, WBCs, and PLTs. We then applied our RNA-extraction
free ddPCR protocol in a reaction volume of 20 μl and 103 isolated EVs
as input to amplify the allele fragment containing the BRAF V600E mu-
tation. As shown in Fig. 4e, the dots above an arbitrary threshold N1 in-
dicate a relative higher number ofmRNA copies detected by NBI-ddPCR,
resulting from single droplets that have encapsulated vesicles carrying
the V600E mutated transcripts. Indeed, samples C02, C03, C11, C14,
C20, and C25 (orange dots) showed 100% matching with data obtained
by pyrosequencing on FFPE tissues, while the samples C04, C09, C19,
C21, and C24 (blue dots) indicated potential new insights on BRAF status
only detected by NBI-ddPCR. To challenge the specificity and sensitivity
of these results, we evaluated the extent of mRNA amplification upon
immunodepletion of CD235a/CD41a positive EVs (Fig. 4e, middle). Un-
expectedly, the number of BRAFV600E copies in the same patients' sam-
pleswere found 4 to 5 fold increasedwith respect to the signal obtained
from the bulk population of EVs, specifically increasing the dynamic
range of sensitivity of the NBI-ddPCR. We also performed another ex-
periment to analyse EVs isolated by anti-CD147, one of the most well-
recognized approaches to enrich for colon cancer derived EVs [57]
[66]. In this case, the diagnostic power was reduced to 83% as compared
with the tissue biopsy results, with a number of copies bb1 in the case of
the sample C25 (0.25 vs 4.48 and 20.05 copies, respectively obtained in
the previous experiments), and to ~34% the concordancewith blue dots.
These data show that a significant fraction of EVs negative for the CD147
antigen can effectively carry BRAFmutated transcripts. Consequently,
NBI is more efficient in comparison to single antibody-mediated enrich-
ment of tumor-derived vesicles.
In order to validate the accuracy of the NBI-ddPCR results, we per-
formed further inspections to the FFPE DNA of the samples from pa-
tients C04, C09, C19, C21, and C24, which resulted BRAF mutation
positive in the EVs but not in the original tumor. These DNAs were sub-
jected to a more sensitive, and clinically approved, allele-specific real-
time PCR (EasyPCR) screen. The sample C19, that showed a value of
Fig. 4.Detection of RNA species enclosed into plasma-isolated EVs and design of a new ddPCR assay to exploit individual, polydisperse EVs for nucleic acids detection. a) Two μl out of 20 of
cDNA synthesized from0.1–4 ngRNA. EV-RNAwere deriving fromplasma samples of 47 healthy donors. ddPCR has been performedwith EvaGreen chemistry. Absolute number ofGAPDH
mRNA copies has been analysed byQuantaSoft Analysis software (BIORAD). b) Thenumber ofGAPDHmRNA copies positively correlatedwith number of PLTs (r=0.62),major producer of
circulating GAPDHmRNA and of microvesicles. c) Design of a new ddPCR assay to encapsulate EVs (50–700 nm) into oil droplets (1400–1600 nm). The number of copies of specific RNAs
present in NBI-isolated EVs can be obtained as function of EV titration. The stochastic entrapment of EVs into oil droplets allow the amplification of the target of interest upon
supplementation of the EvaGreen mix with a *thermostable Reverse Transcriptase enzyme. d) NBI was performed on 1 ml of plasma deriving from patients with colon cancer. The
relative number of EVs is plotted for healthy donors (35–55 years) and for colon cancer patients (64 ± 8 years). One-way ANOVA-Bonferroni have been used to calculate the statistical
significance. e) Left: the copy number of BRAF V600E enclosed in 1000 EVs isolated from 20 colon cancer patients is shown; middle: the copy number of BRAF V600E enclosed in 1000
EVs upon imunodepletion CD235a/CD41a positive EVs is shown; right: the copy number of BRAF V600E in EVs isolated by CD147 antibody. See the Table S3 to evaluate the matching
with BRAF sequencing results performed in tissue biopsy. Numbered lines refer to longitudinal liquid biopsies from the same patient. f) Original plot of the NBI-ddPCR results for the
sample C09, whose RNA from the bulk of EVs has been amplified with BRAF exon-spanning primers and then sequenced. g) Original plot of the NBI-ddPCR results for the sample C12
showing KRAS G12C mutation, subsequently verified by EasyPCR kit.
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mutation, indicating correspondence of the mutation at DNA level and
the effective presence of this cell sub-populations in the tumor. In the
efforts to highlight the presence of the mutated allele by standard se-
quencing in the sample C09, that showed a value of ~6 in the bulk
EVs, we obtained a borderline A peak masked by the prevalence of the
T allele present in the majority of the isolated EV (Fig. 4f). Therefore,
by NBI-ddPCR we identified a previously unreported mutation in BRAF
in at least the 7.5% of the colon cancer patients analysed. Notably, to in-
vestigate also the possibility of detecting a non-vesicular RNA propor-
tion potentially bound by apolipoproteins that could be present in
NBI-isolated samples, we performed immunoprecipitation with APO
A1 and APO B100 antibodies on NBI-isolated EVs from the plasma of
two healthy volunteers [67]. Fig. S7c shows that RNA extracted from
particles recognized by APO A1 and APO B100 antibodies does not con-
tribute to the signal observed for GAPDH or wild-type BRAFmRNAs.
Next, we succeeded to assess on the EVs from the same patients the
prevalent mutations at the level of the exon 2 of KRAS. Remarkably, 3
samples resulted positive to the G12C mutation and 1 sample to the
G12D: the presence of the G12D allele in the sample C12 (with a value
of 1.79 copies/104 EVs) was clearly confirmed by a re-analysis on FFPEDNA (Fig. 4g). Even in the case of KRAS, by NBI-ddPCR we revealed a
previously undetected mutation for at least 3.8% of the patients
analysed.
Collectively, these data show that NBI-ddPCR can be used for liquid
biopsy analyses and to detect clinically relevant predictive and prognos-
tic biomarkers (such as KRAS and BRAF) and open new perspectives to
reveal the extraordinary potential of the EVs towards clinical molecular
diagnostics.
4. Discussion
In this study, we describe the nickel-based isolation (NBI) as a new
approach to selectively enrich heterogeneous (50–700 nm) extracellu-
lar vesicles from biological fluids in timely and cost-effective manner.
We found that EVs captured through electrostatic interactions can be ef-
ficiently dissociated from a nickel-functionalizedmatrix using chelating
agents as excipients, maintaining the properties of a physiological, PBS-
like solution in the elution buffer. This aspect is particularly important
not only to preserve the integrity of EVs which determines at the end
the efficiency in the recovery, but also in view of downstream qualita-
tive and quantitative analyses of the vesicles, as evidenced by
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[28] with a modulation of the ionic strength which can impact fractions
of EVs. By contrast, the concentration of EDTA and citric acid could be
detrimental for chelating calcium /magnesium ions or cofactors impor-
tant for cell phenotype/viability or in vitro assays involving the incuba-
tion with NBI-isolated EVs. We did not observe variations on the
viability (MTT assay) of U87 or colon cancer HCT116 cells exposed for
24 or 48 h to elution buffer 1× or PBS (data not shown). Technically,
we present an optimized procedure that can be readily exploited for re-
search in clinical settings and that could be combinedwithHPLC or size-
exclusion procedure to fractionate EVs within the range of 50–800 nm.
The use of an accurate method to isolate vesicles is mandatory for
correlation analyses since the assessment of particle distribution can
be of relevance for liquid biopsy studies on health and disease states
[47]. The quantitative characterization of NBI-isolated EVs from
human plasma indicated that polydisperse vesicles can expose surface
antigens of different progenitor cells, making difficult any correlation
between the vesicle size and the cell of origin. For this reason, we
refer to EV lineages indicating all the mixed vesicle populations that
are positive to a cell type-distinctive marker and therefore assumed to
have a common parental origin. This concept is corroborated by other
studies that have investigated the presence or absence of specific anti-
gens on plasma-derived or tumor-derived EVs [56].
The proof-of-principle experiments performed with human plasma
including EVs isolated from SK-MEL-28 cells and the melanoma cell-
adhesion molecule CD146 demonstrated that different EV lineages are
unbiasedly recovered by NBI, resulting to a homogeneous suspension
of polydisperse EV lineages. In this context, a targeted
immunodepletion of hematopoietic EV lineages in NBI samples can fa-
cilitate the discovery and characterization of tumor-derived EV lineages.
We have formally proven this possibility by detecting the BRAF V600E
mutated mRNA, whose copy number was enriched in EVs isolated
from plasma of colon cancer patients upon CD235a/CD41a
immunodepletion (Fig. 4e and Table S3).
Early detection is a key challenge that could enable specific interven-
tions to reduce patient mortality and morbidity [70]. First, we designed
a newddPCR assay inwhich the step of RNA extraction can be bypassed,
with the important implications of reducing chances of sample contam-
ination, simplifications of the steps towards the results and the sensitiv-
ity obtained. In this context, the sensitivity over DNA analysis can be
favored by the higher relative number of RNA molecules present in
the sample. Second, the advantage of NBI in detecting mutated BRAF
and KRAS transcripts in comparison with CD147-positive EVs and the
use of a label-free method can provide better sensitivity for tumor-
derived vesicles.
KRAS and BRAF are two genes clinically relevant for the prognostic
role [71,72], and therapeutic options [73] not only for colon cancer.
We have shown that, through liquid biopsy, it is possible to identify
fractions of secreted EVs carrying tumor biomarkers with a sensitivity
and accuracy that led to re-consider the mutational status in at least
10% of the patients analysed. Currently, the analysis of circulating
tumor biomarkers, based on cell-free DNA, shows incomplete sensitiv-
ity in lung cancer [74]. In our proof-of-concept study, despite the
small number of cases analysed, we reached a complete concordance
with the tumor-derived data in detecting BRAF and KRAS mutations
from liquid biopsy. Importantly, some cases showed mutations only
in the secreted EVs, suggesting that NBI-ddPCR could serve to infer
the presence of specific cell sub-populations hardly detectable in tis-
sue biopsy. This possibility could allow a deeper characterization of
tumor heterogeneity and/or its evolution during therapy, with poten-
tial impact for the clinical managements of patients. Addressing the
low fraction of cells that could generate the EV sub-populations de-
tectable by NBI-ddPCR, systematic studies are needed to understand
the threshold specificities and the potential clinical relevance. We be-
lieve these findings can relevantly contribute to the rationalestablishment of EV-based liquid biopsy studies for the future benefit
of clinical diagnostics.
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